Pasithea Therapeutics (NASDAQ:KTTA) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Pasithea Therapeutics (NASDAQ:KTTA) in a research report sent to investors on Monday, Marketbeat.com reports. The firm issued a buy rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Pasithea Therapeutics’ Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.82) EPS and FY2028 earnings at ($0.87) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Monday, December 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.00.

Pasithea Therapeutics Trading Down 0.9%

KTTA opened at $1.16 on Monday. The company has a fifty day moving average price of $0.81 and a two-hundred day moving average price of $0.78. Pasithea Therapeutics has a 1-year low of $0.28 and a 1-year high of $3.85. The company has a market cap of $8.63 million, a P/E ratio of -0.23 and a beta of 0.21.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its earnings results on Thursday, November 13th. The company reported ($0.41) EPS for the quarter.

Insider Activity

In other Pasithea Therapeutics news, Director Lawrence Steinman purchased 133,333 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The stock was bought at an average cost of $0.75 per share, with a total value of $99,999.75. Following the completion of the transaction, the director owned 199,691 shares of the company’s stock, valued at $149,768.25. The trade was a 200.93% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders purchased 199,999 shares of company stock valued at $149,999 over the last three months. Corporate insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Pasithea Therapeutics

Several institutional investors have recently bought and sold shares of the company. AdvisorShares Investments LLC raised its stake in shares of Pasithea Therapeutics by 33.1% in the third quarter. AdvisorShares Investments LLC now owns 257,696 shares of the company’s stock valued at $186,000 after buying an additional 64,149 shares during the period. Citadel Advisors LLC grew its stake in shares of Pasithea Therapeutics by 43.7% during the 3rd quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after acquiring an additional 20,483 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in Pasithea Therapeutics in the 3rd quarter worth about $26,000. Hedge funds and other institutional investors own 23.92% of the company’s stock.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.